Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they’re “undruggable.”

Revolution Medicines is trying to drug the undruggable with small molecules that block the signaling pathways these proteins use to help cancer grow and thrive. With one of its experimental therapies now in early-stage testing under a partnership with a large pharmaceutical company and more compounds in the pipeline, the Redwood City, CA, biotech is preparing to go public to finance its research.

In documents filed with securities regulators late Friday, Revolution set… Read more »

UNDERWRITERS AND PARTNERS